The price-to-earnings ratio for Nutex Health Inc (NASDAQ: NUTX) is 10.27x, which is above its average ratio. Moreover, the 36-month beta value for NUTX is 0.08. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUTX is 3.54M and currently, short sellers hold a 10.26% of that float. On July 03, 2025, NUTX’s average trading volume was 166.32K shares.
NUTX) stock’s latest price update
The stock of Nutex Health Inc (NASDAQ: NUTX) has decreased by -7.22% when compared to last closing price of $131.8. Despite this, the company has experienced a 1.41% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-30 that Nutex Health delivered a blowout Q1 2025, with $51M in free cash flow and 214% y/y revenue growth, driven by arbitration wins. A frank discussion of its equity dilution. The company’s growth is impressive but erratic, with limited visibility and heavy reliance on non-recurring arbitration revenue.
NUTX’s Market Performance
NUTX’s stock has risen by 1.41% in the past week, with a monthly drop of -27.19% and a quarterly rise of 71.27%. The volatility ratio for the week is 8.44% while the volatility levels for the last 30 days are 9.98% for Nutex Health Inc The simple moving average for the last 20 days is 0.29% for NUTX stock, with a simple moving average of 84.11% for the last 200 days.
Analysts’ Opinion of NUTX
Many brokerage firms have already submitted their reports for NUTX stocks, with Maxim Group repeating the rating for NUTX by listing it as a “Buy.” The predicted price for NUTX in the upcoming period, according to Maxim Group is $50 based on the research report published on November 12, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see NUTX reach a price target of $45. The rating they have provided for NUTX stocks is “Buy” according to the report published on September 18th, 2024.
Northland Capital gave a rating of “Outperform” to NUTX, setting the target price at $3 in the report published on February 22nd of the previous year.
NUTX Trading at -9.59% from the 50-Day Moving Average
After a stumble in the market that brought NUTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.64% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUTX starting from Bates Jon Christian, who purchase 1,000 shares at the price of $81.81 back on Apr 08 ’25. After this action, Bates Jon Christian now owns 4,888 shares of Nutex Health Inc, valued at $81,810 using the latest closing price.
Bates Jon Christian, the Chief Financial Officer of Nutex Health Inc, purchase 1,350 shares at $21.46 during a trade that took place back on Aug 22 ’24, which means that Bates Jon Christian is holding 2,277 shares at $28,970 based on the most recent closing price.
Stock Fundamentals for NUTX
Current profitability levels for the company are sitting at:
- 0.32 for the present operating margin
- 0.49 for the gross margin
The net margin for Nutex Health Inc stands at 0.16. The total capital return value is set at 0.34. Equity return is now at value 51.65, with 11.52 for asset returns.
Based on Nutex Health Inc (NUTX), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is 9.32.
Currently, EBITDA for the company is 148.65 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 1.45. The receivables turnover for the company is 2.12for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.27.
Conclusion
To wrap up, the performance of Nutex Health Inc (NUTX) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
